Celltrion Unveils Next-Gen Drug Development Success
- CHICAGO – Celltrion and Celltrion Pharmaceutical will jointly present new anticancer drug data at the American Association for Cancer Research (AACR) 2025 annual meeting,scheduled for April 25-30 in...
- Celltrion is set to announce preclinical results for CT-P72, a multi-antagonist HER2-targeted T cell engager (TCE), on April 27.The drug, co-developed with U.S.
- Celltrion Pharmaceutical will unveil its dual-payload antibody-drug conjugate (ADC) platform technology,CTPH-02,on April 30.
celltrion and Celltrion Pharm too Present Anticancer Drug Data at AACR 2025
Table of Contents
- celltrion and Celltrion Pharm too Present Anticancer Drug Data at AACR 2025
- Celltrion’s Anticancer Drug Advancements: Your Questions Answered
- What’s the Latest News from Celltrion adn Celltrion Pharm regarding Anticancer Drugs?
- What Specifically will Celltrion Present at AACR 2025?
- What is CT-P72 and How Does it Work?
- What is the Importance of celltrion Pharmaceutical’s Presentation at AACR 2025?
- what is an Antibody-Drug Conjugate (ADC)?
- How could the Dual-Payload ADC Platform Benefit cancer Treatment?
- What is the Collaboration strategy Between Celltrion and Celltrion Pharm?
- What are Celltrion’s Pipeline Expansion Plans?
- What is an IND application?
- Has Celltrion Received any recent FDA Approvals?
- What other ADC drugs is Celltrion working on?
- What is the Executive Outlook for Celltrion Group?
- Summary of Key Celltrion Advancements
CHICAGO – Celltrion and Celltrion Pharmaceutical will jointly present new anticancer drug data at the American Association for Cancer Research (AACR) 2025 annual meeting,scheduled for April 25-30 in Chicago.
Celltrion to Unveil Preclinical Data for CT-P72
Celltrion is set to announce preclinical results for CT-P72, a multi-antagonist HER2-targeted T cell engager (TCE), on April 27.The drug, co-developed with U.S. bio company ABPRO, aims to induce cancer cell death by connecting HER2-positive cancer cells and T-cells. This process allows T-cells to bind to both cancer cells,triggering the T-cells to eliminate the cancerous cells.
Celltrion Pharm to Showcase dual-Payload ADC Platform
Celltrion Pharmaceutical will unveil its dual-payload antibody-drug conjugate (ADC) platform technology,CTPH-02,on April 30. This platform combines two types of cell-toxic anticancer payloads, perhaps leading to enhanced efficacy and improved treatment accuracy when combined with antibodies.
Synergistic R&D Efforts
The companies anticipate synergistic research and growth outcomes, with Celltrion focusing on new drug pipeline development and Celltrion Pharmaceutical concentrating on platform technology for next-generation treatments.
Pipeline Expansion plans
Celltrion aims to submit Investigational New Drug (IND) applications for 13 candidate materials by 2028, including nine ADC and four multi-specific antibody candidates. The company intends to rapidly expand its new drug portfolio, building upon its experience in developing antibody biosimilars, and solidify its position as a key player in the new drug sector.
Recent FDA Approval
Celltrion received FDA approval last month for Phase 1 clinical trials of its ADC anticancer drug, CT-P70, which targets CMET, a protein activated in cancer cells that promotes tumor growth. Clinical procedures have commenced. The company plans to submit INDs for additional ADC drugs, such as CT-P71 and CT-P73, and the multi-specific antibody drug CT-P72 later this year.
Executive Outlook
According to a Celltrion Group official, the group’s major subsidiaries will focus on securing new drug candidates and platform technologies through robust R&D capabilities and execution. The goal is to strengthen global competitiveness and achieve notable advancements in the pharmaceutical field.
Celltrion’s Anticancer Drug Advancements: Your Questions Answered
What’s the Latest News from Celltrion adn Celltrion Pharm regarding Anticancer Drugs?
Celltrion and Celltrion Pharmaceutical are gearing up to present new anticancer drug data at the american Association for Cancer research (AACR) 2025 annual meeting in Chicago, scheduled for April 25-30. This collaboration highlights their commitment to advancing cancer treatments.
What Specifically will Celltrion Present at AACR 2025?
Celltrion will unveil preclinical data for CT-P72, a multi-antagonist HER2-targeted T cell engager (TCE), on April 27.
What is CT-P72 and How Does it Work?
CT-P72, co-developed with U.S. bio company ABPRO, is designed to destroy cancer cells by connecting HER2-positive cancer cells and T-cells. This connection enables T-cells to bind to and eliminate cancerous cells.
What is the Importance of celltrion Pharmaceutical’s Presentation at AACR 2025?
Celltrion Pharmaceutical will showcase its dual-payload antibody-drug conjugate (ADC) platform technology, CTPH-02, on April 30. This platform combines two types of cell-toxic anticancer payloads.
what is an Antibody-Drug Conjugate (ADC)?
an antibody-drug conjugate (ADC) is a targeted cancer therapy. It combines an antibody (designed to recognize and bind to specific cancer cells) with a cytotoxic (cell-killing) drug. This allows for the drug to be delivered directly to the cancer cells, minimizing harm to healthy cells.
How could the Dual-Payload ADC Platform Benefit cancer Treatment?
The CTPH-02 platform, which combines two types of cell-toxic anticancer payloads, could possibly lead to enhanced efficacy and improved treatment accuracy when combined with antibodies. This could mean more effective cancer treatment with fewer side effects.
What is the Collaboration strategy Between Celltrion and Celltrion Pharm?
Celltrion and Celltrion Pharmaceutical are collaborating on research and development (R&D). Celltrion will focus on new drug pipeline development, while Celltrion Pharmaceutical will concentrate on platform technology for next-generation treatments. This is intended to create a synergistic effect and accelerate advancements in cancer therapy.
What are Celltrion’s Pipeline Expansion Plans?
Celltrion plans to submit Investigational New Drug (IND) applications for 13 candidate materials by 2028, including nine ADC and four multi-specific antibody candidates. this is part of Celltrion’s strategy to expand its new drug portfolio, leveraging its experience in developing antibody biosimilars.
What is an IND application?
An Investigational New Drug (IND) application is a request to the FDA to allow a new drug to be tested in humans. It includes preclinical data, manufacturing information, and a clinical trial protocol.
Has Celltrion Received any recent FDA Approvals?
Yes, Celltrion recently received FDA approval for Phase 1 clinical trials of its ADC anticancer drug, CT-P70, which targets CMET, a protein activated in cancer cells. Clinical procedures have already commenced.
What other ADC drugs is Celltrion working on?
Celltrion plans to submit INDs for additional ADC drugs,such as CT-P71 and CT-P73,and the multi-specific antibody drug CT-P72 later this year.
What is the Executive Outlook for Celltrion Group?
According to a Celltrion Group official, the subsidiaries will focus on securing new drug candidates and platform technologies via robust R&D capabilities. The goal is to strengthen global competitiveness and achieve notable advancements in the pharmaceutical field.
Summary of Key Celltrion Advancements
| Feature | Description | target Date | Action |
| ————————— | ——————————————————————————————————————- | ——————– | ————————————————————————————————– |
| CT-P72 | Multi-antagonist HER2-targeted T cell engager (TCE); Co-developed with ABPRO | April 27, 2025 (AACR) | presentation of preclinical data |
| CTPH-02 | Dual-payload ADC platform technology | April 30, 2025 (AACR) | Platform Showcase |
| Pipeline Expansion | Submission of 13 IND applications (9 ADCs, 4 multi-specific antibodies) | By 2028 | rapid expansion of new drug portfolio |
| CT-P70 | ADC targeting CMET; phase 1 trials approved | Last Month | Initiated Phase 1 clinical trials |
| Future IND Submissions | CT-P71, CT-P73 (ADCs), and CT-P72 (multi-specific antibody) | Later This Year | Submission of further IND applications |
| Overall Strategy | Focus on securing new drug candidates and platform technologies through robust R&D; strengthen global competitiveness | Ongoing | Advancements in the pharmaceutical field |